Apis Capital Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA

Apis Capital Advisors LLC bought a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $627,000. Apis Capital Advisors LLC owned about 0.08% of Palvella Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in the company. Suvretta Capital Management LLC raised its stake in shares of Palvella Therapeutics by 15.1% during the 3rd quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after buying an additional 107,937 shares during the last quarter. Frazier Life Sciences Management L.P. grew its stake in Palvella Therapeutics by 4.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after acquiring an additional 32,388 shares during the last quarter. Vanguard Group Inc. increased its holdings in Palvella Therapeutics by 202.0% during the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after acquiring an additional 330,847 shares in the last quarter. Federated Hermes Inc. purchased a new position in Palvella Therapeutics during the 3rd quarter valued at about $21,255,000. Finally, Millennium Management LLC acquired a new position in Palvella Therapeutics during the first quarter worth about $7,553,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Insiders Place Their Bets

In other Palvella Therapeutics news, Director Elaine J. Heron purchased 2,400 shares of Palvella Therapeutics stock in a transaction on Friday, February 27th. The shares were bought at an average price of $125.00 per share, with a total value of $300,000.00. Following the purchase, the director directly owned 47,812 shares in the company, valued at $5,976,500. This trade represents a 5.28% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were acquired at an average price of $125.00 per share, for a total transaction of $500,000.00. Following the acquisition, the director directly owned 187,171 shares of the company’s stock, valued at approximately $23,396,375. The trade was a 2.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 20.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Oppenheimer reiterated an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Mizuho upped their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. Canaccord Genuity Group raised their price target on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Finally, Truist Financial set a $210.00 price target on Palvella Therapeutics in a report on Tuesday, February 24th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $184.87.

Palvella Therapeutics Price Performance

NASDAQ:PVLA opened at $122.06 on Friday. The firm has a market cap of $1.45 billion, a PE ratio of -46.41 and a beta of -0.30. The firm has a 50 day simple moving average of $100.75 and a 200-day simple moving average of $86.20. Palvella Therapeutics, Inc. has a 1-year low of $18.23 and a 1-year high of $151.18.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.